

AD _____

Award Number: W81XWH-07-1-0208

TITLE: How MMPs Impact Bone Responses to Metastatic Prostate Cancer

PRINCIPAL INVESTIGATOR: Conor C. Lynch, Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University
Nashville, TN 37203

REPORT DATE: February 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 February 2009		2. REPORT TYPE Annual		3. DATES COVERED 1 Feb 2008 – 30 Jan 2009	
4. TITLE AND SUBTITLE How MMPs Impact Bone Responses to Metastatic Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0208	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Conor C. Lynch, Ph.D. E-Mail: conor.lynch@vanderbilt.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Nashville, TN 37203				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Using an animal model of prostate tumor progression in the bone we have previously shown that MMPs, namely MMP-2,-3,-9 and -13, are overexpressed at the tumor bone interface and these MMPs are for the most part expressed by the host cells of the bone. To test the contribution of MMPs in prostate tumor progression in the bone, we have generated mice that are immunocompromized and deficient for MMP-2,-3 and -9 during the current period. We have found that MMP-9 does not contribute to prostate tumor progression in the bone since no difference in osteolytic or osteoblastic responses between wild type and MMP-9 deficient animals were detected by Faxitron, CT, SPECT and histomorphometry. These results, while negative, are important for the generation of selective MMP inhibitors that lack the deleterious side effects associated with broad spectrum inhibitors. In addition, we have also identified PTHrP as an MMP substrate and postulate that MMP processing of PTHrP may be a mechanism through which MMPs can contribute to tumor induced osteolysis.					
15. SUBJECT TERMS Osteolysis, osteoblastic changes, prostate progression in bone, matrix metalloproteinases, MMPs, receptor activator of nuclear kappa B ligand, RANKL, bone metastasis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 15	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	12
Reportable Outcomes.....	12
Conclusions.....	13
References.....	13

Introduction

This year, in the United States alone, of the 27,350 men who die from prostate cancer, 80% will have evidence of bone metastasis (1, 2). Prostate bone metastases cause several complications for patients such as hypercalcemia, spontaneous bone fracture and debilitating pain that dramatically affects their quality of life. To progress in the bone, the invading prostate tumor cells induce radical changes in bone matrix homeostasis by stimulating osteoblastic and osteolytic changes (3). These changes result in an actively remodeling bone tumor microenvironment, rich in mitogenic signals that promote tumor growth. In turn, the growth of the tumor exacerbates the osteoblastic and osteolytic changes in a manner that has been well described as the 'vicious cycle' (4). Using an animal model of

tumor progression in the bone, we have previously identified a group of enzymes known as matrix metalloproteinases (MMPs) as being highly overexpressed at the tumor bone interface in comparison to the tumor area alone. In a bid to understand the importance of these MMPs, namely MMP-2, -3, -9 and -13, in prostate tumor progression in the bone, we aim to generate MMP null animals and compare those animals to their wild type counterparts. While the MMPs are important in the turnover of the extracellular matrix, it has become apparent that the MMPs are also capable of regulating cell:cell communication by processing various cytokines and growth factors to active soluble forms (5). These soluble factors often influence biological processes including survival, proliferation, angiogenesis and osteoclast activation. Therefore, understanding which MMPs are important in contributing to prostate tumor progression in the bone and identifying the mechanisms that govern the vicious cycle can provide valuable targets for therapeutic development.

Body.....

Accomplishments

Aim 1. *Determine the stromal contribution of MMPs that are markedly overexpressed at the tumor:bone interface namely, MMP-2,-3,-9 and -13 to prostate cancer induced osteoblastic and osteolytic changes in the bone.*


- a) Generate immunocompromised RAG-2^{-/-} mice that are deficient in MMP-2, MMP-3 and MMP-13 by crossing RAG-2^{-/-} mice with MMP^{-/-} mice that are both available on the C57Bl/6 background (Months 1-12).
- b) Using our pre-clinical animal models, we will test the contribution of stromal MMP-9 to tumor induced osteoblastic and osteolytic change in readily available immunocompromised RAG-2^{-/-} MMP-9 deficient mice (Months 1-12).
- c) Test the contribution of stromal MMP-2, MMP-3 and MMP-13 to tumor induced osteoblastic and osteolytic change using our pre-clinical model (Months 11-30).

- d) Identify the expression of stromal MMPs in human clinical samples of prostate bone metastases (Months 20-36).

The proposed animal model in the current program involves the transplantation of moderately differentiated rat prostate adenocarcinoma to the calvaria of immunocompromised wild type and MMP deficient mice. To achieve this, we proposed to cross C57Bl/6 RAG-2 (recombinase activating gene-2) deficient mice with either C57Bl/6 MMP-2, -3 or -13 deficient animals in order to generate F2/F3 animals that are immunocompromised and deficient for the desired MMP. As of January 2009, we have generated RAG-2^{-/-};MMP-2^{-/-}, RAG-2^{-/-};MMP-3^{-/-} and RAG-2^{-/-}; MMP-13^{-/-} animals and have made preliminary observations with these animals in terms of prostate tumor induced osteolytic and osteoblastic changes.

Host MMP-9 impacts angiogenesis in the prostate tumor-bone microenvironment but does not impact tumor induced osteolytic and/or osteoblastic changes.


In the initial 12 months of the project, the PI focused on assessing the impact of host derived MMP-9 in tumor induced osteolytic and osteoblastic changes. In repeated studies, with at least 10 animals per group, we determined that MMP-9 does not have any effect on tumor progression in the bone using both whole animal imaging modalities such as microCT and microSPECT and traditional histomorphometry approaches. While there is a trend



towards a decrease in osteolysis in the MMP-9 deficient animals, this decrease has not proven to be statistically significant (Figure 1). While these data suggest that MMP-9 does not contribute to tumor progression in the bone, it should be stated that the role of MMP-9 in 1) the metastasis of prostate cancer to the bone or 2) in the initial survival/establishment of the prostate tumor cells in the bone microenvironment can not be ruled out since these steps are not recapitulated in our animal model. Previous studies have shown that MMP-9 is important in mediating angiogenesis in the tumor microenvironment (6) and using the endothelial antigen CD-31 as a marker for angiogenesis, we have found decreased angiogenesis in the MMP-9 null group (Figure 1). We are currently preparing a manuscript documenting our findings.

Host MMP-13 has a protective role in the prostate tumor-bone microenvironment

Murine MMP-13 is considered to be the ortholog of human MMP-1, and MMP-13 deficient animals have been reported as having a delay in endochondral ossification during skeletal development with thickened trabecular bone persisting in the animals (7, 8). In collaboration with Dr. Stephen Krane, the PI has generated immunocompromised MMP-13 deficient mice. At this juncture, histological analysis of the calvaria from these animals at 6 weeks of age and their age matched wild type counterparts appear to be similar with respect to the amount of bone and number of osteoclasts (data not shown). Surprisingly, preliminary studies using our



animal model suggest that host MMP-13 plays a protective role in preventing tumor induced osteolytic and osteoblastic changes (Figure 2). At three weeks post implantation, immunocompromised wild type and MMP-13 deficient animals were sacrificed. Histological analysis revealed that in comparison to wild type controls, MMP-13 deficient sections had higher numbers of osteoblasts and osteoclasts which was consistent with increase bone formation and destruction respectively. These data are unexpected since MMP-13 has been described as the rate limiting collagenase for murine skeletal development. Our data, while very preliminary, suggests that in the pathological context of the tumor bone microenvironment, *host MMP-13 inhibits the vicious cycle and plays a protective role in the tumor-bone microenvironment*. The concept of MMPs as playing a protective role during tumor progression has been reported for MMP-3 and MMP-8 during skin carcinogenesis and progression in mice but to our knowledge MMP-13 has not been described as being protective in a pathological context (9, 10). These studies will be repeated again and the molecular mechanisms through which MMP-13 protects against prostate tumor progression in the bone will be a primary focus over the final year of the proposal

Thus far, our data illustrate that MMP-7, -9 and -13 are highly expressed in the prostate tumor-bone microenvironment but on an individual basis, they clearly play very different roles with respect to tumor induced osteoblastic and osteolytic changes. We are currently evaluating the contribution of host MMP-2 and MMP-3 in our model. These preliminary findings support the rationale for delineating the individual roles of MMPs in the pathological context of the prostate tumor-bone microenvironment so that selective inhibitors can be generated that lack the deleterious side effects of broad spectrum inhibitors. Further, identification of the mechanisms through which MMPs act to contribute to or protect against tumor induced osteolytic and osteoblastic changes may also reveal new therapeutic strategies for the treatment of prostate to bone metastases. Therefore, Specific Aim 1 will determine the contribution of MMP-2 and MMP-3 to prostate tumor induced osteolytic and osteoblastic changes while fully exploring the potential protective effect of host MMP-13.


To determine the clinical relevance of host MMPs in tumor progression in the bone, we have been collecting non-identified samples of human prostate to bone metastasis. Through the Department of Orthopaedics and Rehabilitation here at Vanderbilt, we have collected a limited number of samples that will not give us the statistical power necessary to determine the prevalence of MMP expression in human prostate to bone metastases. Therefore, the PI has begun a collaboration with Dr. Bob Vessella, Dept. of Urology, University of Washington. Dr. Vessella has agreed to provide human samples of prostate to bone metastasis (up to 800 if necessary) collected through his rapid warm body autopsy program at the University of Washington (11, 12). The localization of MMPs in these samples will be performed over the final 12 months of the project.

Aim 2. *Identify and test MMP processed substrates that mediate prostate tumor induced osteolytic and osteoblastic change.*

- a) Identify and test candidate MMP substrates that mediate prostate tumor induced osteolytic and osteoblastic change.
- b) Determine the contribution of MMP solubilized RANKL vs. MMP resistant RANKL in mediating osteoclastogenesis


In aim 2, we have taken a candidate approach in a bid to identify the potential factors that MMPs process in order to mediate tumor induced osteolysis. Bone is a rich reservoir of growth factors such as transforming growth factor β (TGF β) and insulin like growth factor-1 (IGF-1) and both of these factors have been implicated in driving the 'vicious cycle' (4). Given that various MMPs have been reported as processing the molecules that keep these growth factors in a latent state such as latency TGF β binding proteins (LTBPs) and IGF binding proteins (IGF-BPs) we envisage that these would be excellent candidate molecules through which MMPs could contribute to osteolytic and osteoblastic effects. Given the labile nature of TGF β we have taken multiple approaches into identifying the activity status of the cytokine in wild type and MMP null animals. Using procedures described by

Barcellos-Hoff et al.(13), we have been able to generate frozen sections of non-decalcified bone using the Cryo-Jane Tape transfer system. This approach allows us to visualize latent and active TGF β in the tumor-bone microenvironment using microscopy (Figure 3). We have also examined the presence of active TGF β using ELISA. We have observed that there is more active TGF β at the tumor bone interface in comparison to the tumor area alone in wild type animals but thus far have found no difference in the levels of active TGF β between wild type, MMP-7 and MMP-9 null animals (Figure 3).



Using these approaches and following up with western blot and immunolocalization studies, we have the ability to rapidly assess if host derived MMPs, such as MMP-2, -3 and -13 are playing a role in the release of active TGF β from the bone.

In the metastatic bone:tumor microenvironment, parathyroid related hormone (PTHrP) has been identified as a powerful mediator of osteolysis (14). Pro-PTHrP has three isoforms that are 139, 141 or 173 amino acids in length. These isoforms are subsequently enzymatically processed to yield the mature form of PTHrP₁₋₃₆ (amino acids 1-36). Thus far the enzymes implicated in generating mature PTHrP have been; endothelin converting enzyme-1 (ECE-1); ECE-2 and neprilysin which are not MMPs but are members of the metazincin family of proteinases. Interestingly, prostate



specific antigen (PSA) which is a serine protease has also been shown to process PTHrP but in a different region that generates a 23 amino acid form of PTHrP₁₋₂₃ (Cramer et al., 1996). This is thought to abolish the activity of the hormone but some studies suggest that smaller molecular weight versions of PTHrP can have differential effects compared to PTHrP₁₋₃₆ (15).

Since PTHrP can be processed by members of the metazincin family and given the presence of MMPs in the tumor bone microenvironment, we asked whether MMPs could process PTHrP. Using recombinant PTHrP₁₋₁₄₁, we observed that MMP-3 and MMP-7 generate mature PTHrP₁₋₃₆ (Figure 4). Further examination by mass spectroscopy revealed that MMP-3 and MMP-7 further processed PTHrP₁₋₃₆ into smaller fragments, namely PTHrP₁₋₁₆, PTHrP₁₇₋₂₆ and PTHrP₂₇₋₃₄. A number of the MMP generated PTHrP products have reported cellular functions. For example, PTHrP₁₋₁₆ has sequence similarities to endothelin-1 (ET-1). ET-1 has been identified as a major factor involved in promoting osteoblastic responses via the ET_A receptor (16). PTHrP₁₋₁₆ has been shown to bind to ET_A in cardiomyocytes but apparently has no impact on ET_A signaling when overexpressed in CHO cells (17, 18). However, the precise role of PTHrP₁₋₁₆ in osteoblast function is unclear. Other MMP-3 generated fragments such as PTHrP₂₇₋₃₆ can mediate protein kinase C signaling via the PTHR-1 receptor (19) but again, the precise role of this fragment in addition to PTHrP₁₇₋₂₆ in osteoblast function remain unclear. *Therefore, delineating the role of these MMP generated PTHrP products on osteoblast behavior will be a major goal over the course of the remainder of the project.*

We have previously demonstrated that membrane bound receptor activator of nuclear κ B ligand (RANKL) which is essential for osteoclast maturation and activation is sensitive to shedding from the cell surface by MMP-3 and MMP-7 (20).




Fig. 5. A: MMP-7 processes RANKL in the juxtamembrane region at amino acid position 142 (see figure 10 for additional information). To generate a non-cleavable mutant RANKL, the methionines at positions 142 and 143 in addition to the proline at position 140 were mutated by single nucleotide substitution using a site directed mutagenesis kit (Stratagene). Methionine to Valine (ATG to GTG) and Proline to Leucine (CCA to CTA) **B:** Wild type and Δ-RANKL full length cDNAs were in vitro translated using the Promega TnT *in vitro* translation system with S³⁵ labeled methionine. **1:** Δ-RANKL alone. **2-3:** Δ-RANKL(2) or wild type RANKL(3) incubated with 100ng of MMP-7 overnight at 37°C. Arrow indicates full length unglycosylated Δ-RANKL at approx 40kDa. Arrow heads denote cleavage products.

We have generated a non-cleavable version of RANKL and are currently testing the ability of the non-cleaved RANKL to stimulate osteoclast activation via direct cell:cell contact (Figure 5).

Key Research Accomplishments.....

- Generated RAG-2;MMP-2, RAG-2;MMP3, RAG-2;MMP-13 null animals
- Observed that host derived MMP-9 does not contribute to tumor progression in the bone but does impact angiogenesis
- Have observed that host MMP-13 plays a protective role in preventing tumor induced osteolytic and osteoblastic changes.
- Have begun the examination human samples of prostate to bone metastasis in collaboration with Dr. Vessella.
- Identified higher levels of TGF β at the tumor bone interface in comparison to the tumor area alone in wild type animals
- Identified that MMP-3 and MMP-7 are capable of generating mature PTHrP
- Have generated a non-cleavable version of RANKL

Reportable Outcomes.....

Manuscripts

Halpern, JL., Bruni-Cardoso, A., Craig, L, Peterson TE., and Lynch, CC. Host matrix metalloproteinase-9 does not impact tumor induced osteolytic/osteoblastic changes in a model of prostate cancer bone metastasis. Manuscript in preparation.

Presentations

Growth Factor and Signaling Symposium, Ames, Iowa, September, 2008

Joint AACR and Metastasis Research Society Meeting, Vancouver, BC, Canada, August, 2008

Tumor host interaction and angiogenesis meeting, Monte Verita, Ascona, Switzerland, October 2007.

Conclusion.....

In previous studies, we have identified that MMPs, namely MMP-2, -3, -9 and -13 are overexpressed at the tumor: bone interface. In the past, human clinical trials involving broad spectrum MMP inhibitors failed due to dose limiting side effects. The principle reason for the failure was due to a lack of understanding as to how MMPs contribute to tumor progression. In animals models of osteolysis, broad spectrum MMP inhibitors have been successful in preventing tumor induced osteolysis and growth (21-23). Therefore, in order to apply MMP inhibitors in the clinical setting, we must identify the individual MMPs that impact tumor progression in the bone. Our initial studies show that host MMP-9 does not contribute to tumor progression in the bone while MMP-13 appears to have a protective effect. These data therefore support the rationale for identifying the contribution of individual MMPs in the prostate-tumor bone microenvironment so that selective MMP inhibitors can be developed that lack the deleterious affects of broad spectrum MMP inhibitors can be developed. To this end, the PI has begun a collaboration with Prof. Qing-Xiang Amy Sang to test the efficacy of selective MMPis in the In year 2, we will continue testing the contribution of MMP-2, MMP-3 and MMP-13 to prostate tumor progression and examining whether MMP processing of PTHrP, RANKL or TGF β are responsible for observed phenotypes in the MMP null tumor-bone microenvironments.

References.....

1. www.cancer.org. Cancer Facts and Figures. American Cancer Society 2008.
2. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 2000; 31: 578-83.
3. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry 2004; 91: 718-29.

4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nature Reviews Cancer* 2002; 2: 584-93.
5. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. *Differentiation* 2002; 70: 561-73.
6. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nature Cell Biology* 2000; 2: 737-44.
7. Inada M, Wang Y, Byrne MH, et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. *Proceedings of the National Academy of Sciences of the United States of America* 2004; 101: 17192-7.
8. Stickens D, Behonick DJ, Ortega N, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice 2. *Development* 2004; 131: 5883-95.
9. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. *Nat Genet* 2003; 35: 252-7.
10. McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. *Cancer Res* 2004; 64: 6965-72.
11. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. *J Urol* 2008; 180: 1154-60.
12. Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. *Clin Exp Metastasis* 2003; 20: 171-80.
13. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. *J Clin Invest* 1994; 93: 892-9.
14. Guise TA. Molecular mechanisms of osteolytic bone metastases. *Cancer* 2000; 88: 2892-8.
15. Ruchon AF, Marcinkiewicz M, Ellefsen K, et al. Cellular localization of neprilysin in mouse bone tissue and putative role in hydrolysis of osteogenic peptides. *J Bone Miner Res* 2000; 15: 1266-74.

16. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. *Proc Natl Acad Sci U S A* 2003; 100: 10954-9.
17. Langlois C, Letourneau M, Turcotte K, Detheux M, Fournier A. PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors. *Peptides* 2005; 26: 1436-40.
18. Schluter KD, Katzer C, Piper HM. A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. *Br J Pharmacol* 2001; 132: 427-32.
19. Miao D, Tong XK, Chan GK, Panda D, McPherson PS, Goltzman D. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. *J Biol Chem* 2001; 276: 32204-13.
20. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL 1. *Cancer Cell* 2005; 7: 485-96.
21. Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. *European Journal of Cancer* 2001; 37: 106-13.
22. Winding B, NicAmhlaoibh R, Misander H, et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. *Clinical Cancer Research* 2002; 8: 1932-9.
23. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. *Journal National Cancer Institute* 2002; 94: 17-25.